| Target Price | €9.59 |
| Price | €7.59 |
| Potential |
26.32%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target CTT - Correios De Portugal, S.A. 2026 .
The average CTT - Correios De Portugal, S.A. target price is €9.59.
This is
26.32%
register free of charge
€10.55
39.03%
register free of charge
€6.62
12.84%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend CTT - Correios De Portugal, S.A. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CTT - Correios De Portugal, S.A. stock has an average upside potential 2026 of
26.32%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 0.97 | 1.29 |
| 14.35% | 33.35% | |
| EBITDA Margin | 16.83% | 15.73% |
| 15.63% | 6.52% |
6 Analysts have issued a sales forecast CTT - Correios De Portugal, S.A. 2025 . The average CTT - Correios De Portugal, S.A. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an CTT - Correios De Portugal, S.A. EBITDA forecast 2025. The average CTT - Correios De Portugal, S.A. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.33 | 0.49 |
| 23.26% | 48.48% | |
| P/E | 14.82 |
6 Analysts have issued a CTT - Correios De Portugal, S.A. forecast for earnings per share. The average CTT - Correios De Portugal, S.A. EPS is
This results in the following potential growth metrics and future valuations:
CTT - Correios De Portugal, S.A....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


